Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLLLydia Scarfò, Paolo Ghia, Andrea Ferrario et al.|Blood|2022Cited by 10
P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORTLydia Scarfò, Paolo Ghia, Silvia Heltai et al.|HemaSphere|2023Cited by 2
Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve StudyElisabetta Albi, Paolo Ghia, Lydia Scarfò et al.|Blood|2023Cited by 2
P1517: HUMORAL AND CELLULAR IMMUNE RESPONSES TO SARS-COV-2 NATURAL INFECTION OR VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLLAlessandro Campanella, Paolo Ghia, Antonella Capasso et al.|HemaSphere|2023Cited by 0